(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
8 February 2007 (08.02.2007)

PCT

(10) International Publication Number
WO 2007/014918 A1

(51) International Patent Classification:
C07K 5/078 (2006.01) *A61P 31/14* (2006.01)
A61K 31/4709 (2006.01) *C07K 5/06* (2006.01)

(21) International Application Number:
PCT/EP2006/064812

(22) International Filing Date: 28 July 2006 (28.07.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
05107066.2 29 July 2005 (29.07.2005) EP
06101278.7 3 February 2006 (03.02.2006) EP

(71) Applicants *(for all designated States except US)*: **TIBOTEC PHARMACEUTICALS LTD.** [IE/IE]; Eastgate Village, Eastgate, Little Island, Co Cork (IE). **MEDIVIR AB** [SE/SE]; Lunastigen 7, S-141 44 Huddinge (SE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DE KOCK, Herman, Augustinus** [BE/BE]; Wolfseind 10, B-2370 Arendonk (BE). **RABOISSON, Pierre, Jean-Marie, Bernard** [FR/BE]; Sint Pancratiuslaan 26, B-1933 Sterrebeek (BE). **SIMMEN, Kenneth, Alan** [GB/BE]; Boterbloemenlaan 35, B-3080 Tervuren (BE). **LINDSTRÖM, Mats, Stefan** [SE/SE]; Medivir AB, Lunastigen 7, S-141 44 Huddinge (SE). **KAHNBERG, Pia, Cecilia** [SE/SE]; Medivir AB, Lunastigen 7, S-141 44 Huddinge (SE). **ANTONOV, Dmitry** [RU/SE]; Medivir AB, Lunastigen 7, S-141 44 Huddinge (SE). **NILSSON, Karl, Magnus** [SE/SE]; Medivir AB, Lunastigen 7, S-141 44 Huddinge (SE). **SAMUELSSON, Bengt, Bertil** [SE/SE]; Medivir AB, Lunastigen 7, S-141 44 Huddinge (SE). **ROSENQUIST, Åsa, Annica, Kristina** [SE/SE]; Medivir AB, Lunastigen 7, S-141 44 Huddinge (SE).

(74) Agent: **DAELEMANS, Frank**; Tibotec-Virco Comm. VA, J & J Patent Law Department, Generaal De Wittelaan L 11B 3, B-2800 Mechelen (BE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

[Continued on next page]

(54) Title: MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS



(I)

(57) Abstract: Inhibitors of HCV of formula (I), and the *N*-oxides, salts, and stereoisomers thereof, wherein the dashed line represents an optional double bond between atoms C7 and C8; R^1 is hydrogen or C_{1-6}alkyl; R^2 is hydrogen or C_{1-6}alkyl; and n is 3, 4, 5, or 6; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I) are provided. Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.

WO 2007/014918 A1

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.